ESC 2022 | INVICTUS and PRE18FFIR

On the 3erd day of the European Cardiology Congress 2022 the INVICTUS study was presented, including 4565 patients with atrial fibrillation secondary to rheumatism driven CAD. The aim of this study was to compare the use of Rivaroxaban vs vitamin K antagonists (VKA) in this populations. Mean age was 50 and most patients were women. 

ESC 2022

Primary end point was stroke, systemic thromboembolism, AMI, or cardiovascular death. Study outcomes resulted in 560 primary end point events in the rivaroxaban group vs 446 events in the VKA group (HR 1.25; 95% CI 1.10-1.41). On individual analysis, Rivaroxaban increased the risk of death by 23% and stroke by 37%. However, there were no differences in risk of bleeding between the groups. Drug discontinuation was more frequent in the Rivaroxaban group. 

Among rivaroxaban patients, when looking at RIN valued before study kickoff, within therapeutic range, it was 33%, and at follow-up, it reached 64% in 4 years. 

The use of vitamin K antagonists should be the standard treatment for rheumatic atrial fibrillation. We need further study to properly assess the different therapies for this special population. 

On the other hand, a multicenter prospective study was presented, the PRE18FFIR, which used sodium fluoride positron emission tomography scan (PET) to identify vulnerable plaque without the need for intravascular ultrasound imaging, predicting the risk of future cardiovascular events. 704 AMI and multivessel patients were included. They all received PET and coronary CT angiography and were followed up to 2 years. 

Read also: ESC 2022 | SECURE Trial.

There were no differences between patients with active coronary microcalcification and those who did not present any. However, when looking at cardiovascular death or AMI, events rate was higher among patients with positive PET imaging for CMA. 

This study shows an important role for PET in the assessment of cardiovascular risk. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...